The US Food and Drug Administration has expanded the indication for the long-acting C5 complement inhibitor, ravulizumab , to include adults with anti–aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder .
In CHAMPION-NMOSD, the primary endpoint was met; none of the 58 patients taking ravulizumab had a relapse during treatment vs 20 patients who had a relapse in the placebo group of PREVENT (relapse risk reduction, 98.6%;NMOSD is a rare inflammatory syndrome of the central nervous system and can cause irreversible disability. The disorder affects an estimated 6000 adults in the United States.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: